The 2020 FASEB Science Research Conference on Translational Neuroimmunology: From Mechanisms to Therapeutics, June 29-30, 2020.
The 2020 FASEB Science Research Conference on Translational Neuroimmunology: From Mechanisms to Therapeutics, June 29-30, 2020.
复制标题
DOI：
10.1096/fj.202002065
复制
发表时间：
2020-11
期刊：
影响因子：
--
通讯作者：
Segal BM
中科院分区：
文献类型：
--
作者：
Lane TE;Segal BM
翻译神经免疫学会议：从机制到治疗，于6月29-30日举行。这次会议是FASEB在新冠肺炎大流行后通过完全虚拟的形式举行的第一次SRC。它原定于7月19-22日在巴布森执行会议(巴布森，马萨诸塞州)上举行。在FASEB领导层做出艰难的决定，在整个夏天取消所有面对面的SRC，并强烈鼓励组织者举办虚拟会议之前，FASEB的领导层做出了艰难的决定。当我们被要求组织第一次虚拟会议时，我们最初关心的是科学内容、陈述方式以及会议主席、发言者和听众之间互动机会的变化。尽管如此，我们决定继续进行，鉴于1通信的重要性：美国加州大学欧文分校神经生物学和行为系，邮编：92697，电子邮件：tlane@uci。艾杜。作者贡献：特莱恩和BM西格尔同样对本报告的整体设计和内容编辑做出了贡献。科恩博士在会议开始时对人类脱髓鞘疾病的疾病修饰疗法(DMT)进行了出色的最新概述。他谈到了与MS患者的需求未得到满足相关的几个问题，一个问题是，与推出效力较低但更安全的药物并根据需要升级相比，治疗新诊断的具有更高风险的高效力DMT是否更有利。可用于复发-缓解型多发性硬化患者的DMT在进展性多发性硬化症中效果不佳，并且不能促进受损中枢神经系统的修复或功能恢复。科恩博士的讲话最后指出，需要继续努力，开发更好的方法来评估复发和进展型疾病患者的疾病活动性和治疗反应。
The Translational Neuroimmunology Conference: From Mechanisms to Therapeutics was held June 29-30. This meeting was FASEB’s first SRC that was conducted via a fully virtual format, consequent to the COVID-19 pandemic. It was originally scheduled to be held on July 19-22 at the Babson Executive Conference (Babson, MA. USA), before FASEB leadership made the difficult decision to cancel all in-person SRCs through the summer and strongly encouraged organizers to conduct virtual conferences. When we were asked to organize the first virtual conference, we were initially concerned about changes to scientific content, mode of presentation, and opportunities for interactions between the session chairs, speakers and audience. Nevertheless, we decided to proceed, in light of the importance of1Correspondence: Department of Neurobiology and Behavior, University of California, Irvine, CA 92697, USA; tlane@ uci. edu. Author contributions: TE Lane and BM Segal equally contributed to the overall design and content editing of this report. Dr. Cohen led off the meeting with an outstanding state-of-the-art overview of disease-modifying therapies (DMTs) for the human demyelinating disease MS. He addressed several issues related to unmet needs for patients with MS. One question concerned whether it is more beneficial to treat newly diagnosed patients with highly potent DMTs that carry higher risks, as opposed to initiating less potent but safer drugs and escalating as needed. Available DMTs for patients with the relapsing-remitting form of MS are not as effective in progressive MS, and do not promote repair of the damaged CNS nor functional recovery. Dr. Cohen’s talk concluded by indicating that continuing efforts are needed to develop better methods for evaluating both disease activity and treatment responses in patients with both relapsing and progressive forms of disease.